An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Phase 1 Completed 16 enrolled Alumis Inc

Non-randomizedParallel-groupSingle-blindTreatment

Summary

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.

Timeline

Start: 2025-04-23
Primary completion: 2025-08-01
Completion: 2025-08-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENVUCITINIB	Small molecule	—	Oral

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Summary

Timeline

Drugs

Indications